
Idiopathic Pulmonary Fibrosis - Drug Pipeline Landscape, 2023
Description
Idiopathic Pulmonary Fibrosis - Drug Pipeline Landscape, 2023
Idiopathic pulmonary fibrosis (IPF) is an irreversible, unpredictable, and fatal disease that makes breathing difficult and causes permanent damage to the lungs. With IPF, progressive scarring, or fibrosis of the lungs, prevents muscles, the heart, and other organs from receiving enough oxygen to work properly. IPF typically occurs in people older than 50, affecting slightly more men than women.
Idiopathic pulmonary fibrosis (IPF) can cause scarring in the spaces between the air sacs in the lungs, this makes it more difficult for oxygen to pass into bloodstream. The damage can be caused by many different factors including long-term exposure to certain toxins, certain medical conditions, radiation therapy and some medications.
Signs and symptoms of idiopathic pulmonary fibrosis may include shortness of breath (dyspnea), a dry cough, fatigue, unexplained weight loss, aching muscles, and joints, widening and rounding of the tips of the fingers or toes (clubbing).
Doctors most often diagnose idiopathic pulmonary fibrosis by asking about symptoms. The tests include chest x-ray, high-resolution chest CT, exercise test, biopsy, pulse oximetry and arterial blood gas tests and spirometry.
The most common investigative treatments include two drugs, nintedanib (Ofev) and pirfenidone (Esbriet), oxygen therapy and pulmonary rehabilitation. Symptoms can be eased through lifestyle changes and home remedies like taking healthy food, exercise, quit smoking, get a flu shot and reducing stress.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Idiopathic Pulmonary Fibrosis treatment such as BI 1015550, Pamrevlumab, PRM-151, Treprostinil and others. Key players involved in the development of therapies to treat Idiopathic Pulmonary Fibrosis are FibroGen, Boehringer Ingelheim, Hoffmann-La Roche, United Therapeutics, EmphyCorp Inc and others. One drug is under late-stage pre-registration, four drugs are in Phase III clinical trials and 20+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Idiopathic Pulmonary Fibrosis (IPF) - Drug Pipeline Landscape, 2023 report provides an overview of the Idiopathic Pulmonary Fibrosis (IPF) pipeline drugs. This report covers detailed insights on Idiopathic Pulmonary Fibrosis (IPF) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Idiopathic Pulmonary Fibrosis (IPF) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Idiopathic pulmonary fibrosis (IPF) is an irreversible, unpredictable, and fatal disease that makes breathing difficult and causes permanent damage to the lungs. With IPF, progressive scarring, or fibrosis of the lungs, prevents muscles, the heart, and other organs from receiving enough oxygen to work properly. IPF typically occurs in people older than 50, affecting slightly more men than women.
Idiopathic pulmonary fibrosis (IPF) can cause scarring in the spaces between the air sacs in the lungs, this makes it more difficult for oxygen to pass into bloodstream. The damage can be caused by many different factors including long-term exposure to certain toxins, certain medical conditions, radiation therapy and some medications.
Signs and symptoms of idiopathic pulmonary fibrosis may include shortness of breath (dyspnea), a dry cough, fatigue, unexplained weight loss, aching muscles, and joints, widening and rounding of the tips of the fingers or toes (clubbing).
Doctors most often diagnose idiopathic pulmonary fibrosis by asking about symptoms. The tests include chest x-ray, high-resolution chest CT, exercise test, biopsy, pulse oximetry and arterial blood gas tests and spirometry.
The most common investigative treatments include two drugs, nintedanib (Ofev) and pirfenidone (Esbriet), oxygen therapy and pulmonary rehabilitation. Symptoms can be eased through lifestyle changes and home remedies like taking healthy food, exercise, quit smoking, get a flu shot and reducing stress.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Idiopathic Pulmonary Fibrosis treatment such as BI 1015550, Pamrevlumab, PRM-151, Treprostinil and others. Key players involved in the development of therapies to treat Idiopathic Pulmonary Fibrosis are FibroGen, Boehringer Ingelheim, Hoffmann-La Roche, United Therapeutics, EmphyCorp Inc and others. One drug is under late-stage pre-registration, four drugs are in Phase III clinical trials and 20+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Idiopathic Pulmonary Fibrosis (IPF) - Drug Pipeline Landscape, 2023 report provides an overview of the Idiopathic Pulmonary Fibrosis (IPF) pipeline drugs. This report covers detailed insights on Idiopathic Pulmonary Fibrosis (IPF) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Idiopathic Pulmonary Fibrosis (IPF) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
362 Pages
- 1. Introduction
- 1.1 Idiopathic Pulmonary Fibrosis - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Idiopathic Pulmonary Fibrosis
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Idiopathic Pulmonary Fibrosis - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Late Stage Drugs - Pre-Registration
- 5.1.1 N115 Non-Steroidal Nasal Spray
- 5.2 Clinical Stage Drugs - Phase III
- 5.2.1 BI 1015550
- 5.2.2 Pamrevlumab
- 5.2.3 PRM-151
- 5.2.4 Treprostinil
- 5.3 Clinical Stage Drugs - Phase II
- 5.3.1 AMB-05X
- 5.3.2 AP01
- 5.3.3 Belumosudil
- 5.3.4 BMS-986278
- 5.3.5 C21
- 5.3.6 CC-90001
- 5.3.7 CSL312
- 5.3.8 ENV-101
- 5.3.9 GB0139
- 5.3.10 HEC585
- 5.3.11 HZN-825
- 5.3.12 Jaktinib Dihydrochloride Monohydrate
- 5.3.13 LTP001
- 5.3.14 LYT-100
- 5.3.15 MG-S-2525
- 5.3.16 MN-001
- 5.3.17 NP-120
- 5.3.18 Orvepitant Maleate
- 5.3.19 PLN-74809
- 5.3.20 REGEND 001
- 5.3.21 RXC007
- 5.3.22 Saracatinab
- 5.3.23 Setanaxib
- 5.3.24 TAS-115
- 5.3.25 TTI-101
- 5.3.26 VAY736
- 5.3.27 ZSP1603
- 5.4 Clinical Stage Drugs - Phase I
- 5.4.1 AC-003
- 5.4.2 AK3280
- 5.4.3 AMP945
- 5.4.4 AZD5055
- 5.4.5 BBT-877
- 5.4.6 BLD-0409
- 5.4.7 Brilaroxazine
- 5.4.8 CBS001
- 5.4.9 CG-745
- 5.4.10 CPL-116
- 5.4.11 DWN12088
- 5.4.12 EI-1071
- 5.4.13 EXCL-100
- 5.4.14 Human umbilical cord mesenchymal stem cell
- 5.4.15 Ifetroban Sodium
- 5.4.16 IM156
- 5.4.17 INS018_055
- 5.4.18 LASN01
- 5.4.19 LTI-03
- 5.4.20 MIT-001
- 5.4.21 MTX652
- 5.4.22 NIP292
- 5.4.23 ORIN1001
- 5.4.24 PBF-1129
- 5.4.25 PMG1015
- 5.4.26 PRS-220
- 5.4.27 QR-056-1
- 5.4.28 Rodatristat Ethyl
- 5.4.29 SHR-1906
- 5.4.30 TDI01
- 5.4.31 TRK-250
- 5.5 Early Stage Drugs - Preclinical
- 5.5.1 554-001
- 5.5.2 AD-214
- 5.5.3 AGMB 447
- 5.5.4 AJ303
- 5.5.5 AK0707
- 5.5.6 ALD-R491
- 5.5.7 ANG-3070
- 5.5.8 Anti-IL-6R antibody
- 5.5.9 APT-101
- 5.5.10 ARO-MMP7
- 5.5.11 Atezolizumab
- 5.5.12 Axatilimab
- 5.5.13 BBT 301
- 5.5.14 BBT-209
- 5.5.15 Bemcentinib
- 5.5.16 CB5138-3
- 5.5.17 CHF10067
- 5.5.18 CIT-013
- 5.5.19 Cymerus MSCs
- 5.5.20 Drug for Idiopathic Pulmonary Fibrosis
- 5.5.21 Drug for IPF
- 5.5.22 EXP01
- 5.5.23 FBM5712
- 5.5.24 FP-020
- 5.5.25 GED-0507
- 5.5.26 GLPG-4605
- 5.5.27 GP532
- 5.5.28 HCW9218
- 5.5.29 HL001
- 5.5.30 HM15211
- 5.5.31 HTPEP-001
- 5.5.32 IBIO-100
- 5.5.33 INV-200
- 5.5.34 KIN001-IPF
- 5.5.35 Larazotide
- 5.5.36 Lis-018
- 5.5.37 LPAR1 antagonist antibody
- 5.5.38 MFC-1040
- 5.5.39 MNKD-501
- 5.5.40 MORF-627
- 5.5.41 MORF-720
- 5.5.42 MRG-229
- 5.5.43 NLRP3 antisense oligonucleotides
- 5.5.44 NPT-0025
- 5.5.45 NVP-13/-19
- 5.5.46 NXC680
- 5.5.47 NXP002
- 5.5.48 OATD-01
- 5.5.49 OCF-203
- 5.5.50 OGB21502
- 5.5.51 OLX-201A
- 5.5.52 Oral HY209
- 5.5.53 OXC-201
- 5.5.54 Oxysterol lead compounds
- 5.5.55 PulmoStem
- 5.5.56 QR-053
- 5.5.57 QR-055
- 5.5.58 QR-056-2
- 5.5.59 RBM-006
- 5.5.60 RBO-0618
- 5.5.61 ROCK2
- 5.5.62 RPI-002F
- 5.5.63 SAN903
- 5.5.64 SM-17
- 5.5.65 SPL-334
- 5.5.66 TOP-V122
- 5.5.67 TXR-1002
- 5.5.68 TXR-1007
- 5.5.69 XFB-19
- 5.6 Early Stage Drugs - Discovery
- 5.6.1 AirCyte-AEC
- 5.6.2 AR-001
- 5.6.3 Drug for Idiopathic Pulmonary Fibrosis
- 5.6.4 Drug for Idiopathic Pulmonary Fibrosis
- 5.6.5 Drug for Idiopathic Pulmonary Fibrosis
- 5.6.6 Drug for Idiopathic Pulmonary Fibrosis
- 5.6.7 Drug for Idiopathic Pulmonary Fibrosis
- 5.6.8 Gene Therapy for Idiopathic Pulmonary Fibrosis
- 5.6.9 Gene Therapy for Idiopathic Pulmonary Fibrosis
- 5.6.10 ICRB 002
- 5.6.11 KITCL27
- 5.6.12 P007
- 5.6.13 P013
- 5.6.14 PT002
- 5.6.15 PXS-5382
- 5.6.16 Small Molecules for Idiopathic Pulmonary Fibrosis
- 5.6.17 TGF-Beta
- 5.6.18 Vasoactive Intestinal Peptide
- 5.6.19 I±VAY1/T±VAY6 integrin
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 9 Meters Biopharma Inc
- 9.2 AbbVie Inc
- 9.3 Accro Bioscience Suzhou Co Ltd
- 9.4 AdAlta Ltd
- 9.5 Aeon Respire Inc
- 9.6 AgomAb Therapeutics NV
- 9.7 Algernon Pharmaceuticals
- 9.8 Altavant Sciences Inc
- 9.9 Altay Therapeutics Inc
- 9.10 Aluda Pharmaceuticals Inc
- 9.11 AmMax Bio Inc
- 9.12 Amniotics AB
- 9.13 Amplia Therapeutics Ltd
- 9.14 AnaMar AB
- 9.15 Angion Biomedica Corp
- 9.16 Annji Pharmaceutical Co Ltd
- 9.17 Apaxen
- 9.18 APIE Therapeutics Inc
- 9.19 Aria Pharmaceuticals Inc
- 9.20 Ark Biosciences Inc
- 9.21 Arrowhead Pharmaceuticals
- 9.22 AstraZeneca
- 9.23 Avalyn Pharma Inc
- 9.24 BerGenBio ASA
- 9.25 Blade Therapeutics
- 9.26 Boehringer Ingelheim
- 9.27 Bridge Biotherapeutics Inc
- 9.28 Bristol-Myers Squibb
- 9.29 Celgene
- 9.30 CellionBioMed Inc
- 9.31 Celon Pharma SA
- 9.32 Centessa Pharmaceuticals Plc
- 9.33 Chengdu Huitai Biomedicine Co Ltd
- 9.34 Chiesi Farmaceutici S.p.A.
- 9.35 Citryll BV
- 9.36 CohBar Inc
- 9.37 CrystalGenomics Inc
- 9.38 CSL Behring
- 9.39 Cumberland Pharmaceuticals
- 9.40 Cynata Therapeutics Ltd
- 9.41 Daewoong Pharmaceutical Co. LTD
- 9.42 DICE Therapeutics Inc
- 9.43 Elixiron Immunotherapeutics Inc
- 9.44 EmphyCorp Inc
- 9.45 Endeavor Biomedicines Inc
- 9.46 Endogena Therapeutics Inc
- 9.47 E-Therapeutics Plc
- 9.48 Ethris GmbH
- 9.49 Excalibur Pharmaceuticals, Inc.
- 9.50 Exorphia Co Ltd
- 9.51 Eyestem Research Pvt Ltd
- 9.52 Faknostics LLC
- 9.53 FibroGen
- 9.54 Foresee Pharmaceuticals Co Ltd
- 9.55 Galapagos NV
- 9.56 Galecto Biotech AB
- 9.57 Genentech Inc
- 9.58 Genflow Biosciences Srl
- 9.59 GenKyoTex SA
- 9.60 Genome Protection Inc
- 9.61 Genosco Inc
- 9.62 Graviton Bioscience Corporation
- 9.63 Guangdong Hengrui Pharmaceutical Co Ltd
- 9.64 Guangdong Raynovent Biotech Co Ltd
- 9.65 H4Orphan Pharma
- 9.66 Hanmi Pharmaceuticals Co Ltd
- 9.67 HCW Biologics Inc
- 9.68 Hoffmann-La Roche
- 9.69 Horizon Pharma Ireland Ltd
- 9.70 IBio Inc
- 9.71 Immunomet Therapeutics Inc
- 9.72 InCerebro Co Ltd
- 9.73 InSilico Medicine Hong Kong Limited
- 9.74 INVENT Pharmaceuticals Inc
- 9.75 Inventiva SA
- 9.76 Ionis Pharmaceuticals Inc
- 9.77 Kadmon Corporation LLC
- 9.78 Kinarus AG
- 9.79 Kither Biotech Srl
- 9.80 Lassen Therapeutics 1 Inc
- 9.81 Lispiro LLC
- 9.82 Lung Therapeutics Inc
- 9.83 MannKind Corp
- 9.84 Max Biopharma Inc
- 9.85 MediciNova
- 9.86 Metagone Biotech Inc
- 9.87 Mission Therapeutics Ltd
- 9.88 MitoImmune Therapeutics Inc
- 9.89 Molecure SA
- 9.90 NB Health Laboratory Co Ltd
- 9.91 Nerre Therapeutics Ltd
- 9.92 Nexel Co Ltd
- 9.93 Nextgen Bioscience
- 9.94 Nogra Pharma Ltd
- 9.95 Novartis Pharmaceuticals
- 9.96 Nuformix Plc
- 9.97 Ocean Biomedical Inc
- 9.98 OliX Pharmaceuticals Inc
- 9.99 Omega Therapeutics Inc
- 9.100 Onegene Biotechnology Inc
- 9.101 Orinove, Inc
- 9.102 Oxcia AB
- 9.103 Palo BioFarma SL
- 9.104 Pharmaxis Ltd
- 9.105 Pieris Australia Pty Ltd
- 9.106 Pliant Therapeutics Inc.
- 9.107 Pulmongene Ltd
- 9.108 PulmoSIM Therapeutics
- 9.109 PureTech
- 9.110 RDS2 Solutions Inc
- 9.111 Redx Pharma Plc
- 9.112 Regend Therapeutics
- 9.113 Rejuvenation Technologies Inc
- 9.114 Resolute Pharma Inc
- 9.115 Reviva Pharmaceuticals Inc
- 9.116 Ribomic Inc
- 9.117 Rubedo Life Sciences Inc
- 9.118 Saje Pharma LLC
- 9.119 Saniona AB
- 9.120 Shanghai Life Science & Technology
- 9.121 Shaperon Inc
- 9.122 Sinomab
- 9.123 Sunshine Lake Pharma Co Ltd
- 9.124 Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- 9.125 Syndax Pharmaceuticals Inc
- 9.126 Taiho Pharmaceutical Co Ltd
- 9.127 The National Institutes of Pharmaceutical R&D Co Ltd China
- 9.128 Thirona Bio Inc
- 9.129 Tiziana Life Sciences Plc
- 9.130 Topadur Pharma AG
- 9.131 Toray Industries Inc
- 9.132 Tvardi Therapeutics Inc
- 9.133 Ube Industries Ltd
- 9.134 United Therapeutics
- 9.135 Velvio GmbH
- 9.136 Vicore Pharma AB
- 9.137 Viridian Therapeutics Inc
- 9.138 Wuhan Createrna Science and Technology
- 9.139 Xfibra Inc
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Idiopathic Pulmonary Fibrosis
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - BI 1015550/Boehringer Ingelheim
- Table 2.2 Clinical Trial Details - Pamrevlumab /FibroGen
- Table 2.3 Clinical Trial Details - PRM-151/Hoffmann-La Roche
- Table 2.4 Clinical Trial Details - Treprostinil /United Therapeutics
- Table 2.5 Clinical Trial Details - AMB-05X/AmMax Bio Inc
- Table 2.6 Clinical Trial Details - AP01/Avalyn Pharma Inc
- Table 2.7 Clinical Trial Details - Belumosudil/Kadmon Corporation LLC
- Table 2.8 Clinical Trial Details - BMS-986278/Bristol-Myers Squibb
- Table 2.9 Clinical Trial Details - C21/Vicore Pharma AB
- Table 2.10 Clinical Trial Details - CC-90001/Celgene
- Table 2.11 Clinical Trial Details - CSL312/CSL Behring
- Table 2.12 Clinical Trial Details - ENV-101/Endeavor Biomedicines Inc
- Table 2.13 Clinical Trial Details - GB0139 /Galecto Biotech AB
- Table 2.14 Clinical Trial Details - HEC585 /Sunshine Lake Pharma Co Ltd
- Table 2.15 Clinical Trial Details - HZN-825/Horizon Pharma Ireland Ltd
- Table 2.16 Clinical Trial Details - Jaktinib Dihydrochloride Monohydrate/Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Table 2.17 Clinical Trial Details - LTP001/Novartis Pharmaceuticals
- Table 2.18 Clinical Trial Details - LYT-100/PureTech
- Table 2.19 Clinical Trial Details - MG-S-2525/Metagone Biotech Inc
- Table 2.20 Clinical Trial Details - MN-001/MediciNova
- Table 2.21 Clinical Trial Details - NP-120/Algernon Pharmaceuticals
- Table 2.22 Clinical Trial Details - Orvepitant Maleate/Nerre Therapeutics Ltd
- Table 2.23 Clinical Trial Details - PLN-74809/Pliant Therapeutics Inc.
- Table 2.24 Clinical Trial Details - REGEND 001/Regend Therapeutics
- Table 2.25 Clinical Trial Details - RXC007 /Redx Pharma Plc
- Table 2.26 Clinical Trial Details - Saracatinab/AstraZeneca
- Table 2.27 Clinical Trial Details - VAY736 /Novartis Pharmaceuticals
- Table 2.28 Clinical Trial Details - ZSP1603/Guangdong Raynovent Biotech Co Ltd
- Table 2.29 Clinical Trial Details - AK3280 /Ark Biosciences Inc
- Table 2.30 Clinical Trial Details - AMP945/Amplia Therapeutics Ltd
- Table 2.31 Clinical Trial Details - AZD5055/AstraZeneca
- Table 2.32 Clinical Trial Details - BBT-877/Bridge Biotherapeutics Inc
- Table 2.33 Clinical Trial Details - BLD-0409/Blade Therapeutics
- Table 2.34 Clinical Trial Details - DWN12088/Daewoong Pharmaceutical Co. LTD
- Table 2.35 Clinical Trial Details - EXCL-100/Excalibur Pharmaceuticals, Inc.
- Table 2.36 Clinical Trial Details - Human umbilical cord mesenchymal stem cell/Shanghai Life Science & Technology
- Table 2.37 Clinical Trial Details - Ifetroban Sodium/Cumberland Pharmaceuticals
- Table 2.38 Clinical Trial Details - INS018_055/InSilico Medicine Hong Kong Limited
- Table 2.39 Clinical Trial Details - LTI-03/Lung Therapeutics Inc
- Table 2.40 Clinical Trial Details - MIT-001/MitoImmune Therapeutics Inc
- Table 2.41 Clinical Trial Details - NIP292 /The National Institutes of Pharmaceutical R&D Co Ltd China
- Table 2.42 Clinical Trial Details - ORIN1001/Orinove, Inc
- Table 2.43 Clinical Trial Details - PMG1015/Pulmongene Ltd
- Table 2.44 Clinical Trial Details - PRS-220/Pieris Australia Pty Ltd
- Table 2.45Clinical Trial Details - SHR-1906/Guangdong Hengrui Pharmaceutical Co Ltd
- Table 2.46 Clinical Trial Details - TRK-250/Toray Industries Inc
- Table 2.47 Clinical Trial Details - ANG-3070/Angion Biomedica Corp
- Table 2.48 Clinical Trial Details - ARO-MMP7/Arrowhead Pharmaceuticals
- Table 2.49 Clinical Trial Details - Atezolizumab /Genentech Inc
- Table 2.50 Clinical Trial Details - CHF10067/Chiesi Farmaceutici S.p.A.
- Table 2.51 Clinical Trial Details - XFB-19/Xfibra Inc
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Idiopathic Pulmonary Fibrosis, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Idiopathic Pulmonary Fibrosis, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Idiopathic Pulmonary Fibrosis, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Idiopathic Pulmonary Fibrosis, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.